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Apoptotic tumor cell-Derived 
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Institute, Edinburgh, United Kingdom
Cells undergoing apoptosis produce heterogeneous populations of membrane delimited 
extracellular vesicles (Apo-EVs) which vary not only in size—from tens of nanometers to 
several microns—but also in molecular composition and cargo. Apo-EVs carry a variety 
of potentially biologically active components, including small molecules, proteins, and 
nucleic acids. Larger forms of Apo-EVs, commonly termed “apoptotic bodies,” can carry 
organelles, such as mitochondria and nuclear fragments. Molecules displayed on the 
surface of extracellular vesicles (EVs) can contribute substantially to their size, as well as 
their functions. Thus far, relatively little is known of the functional significance of Apo-EVs 
apart from their roles in fragmentation of dying cells and indicated immunomodulatory 
activities. Here, we discuss EV production by dying tumor cells and consider the possible 
roles of Apo-EVs in a cell death-driven sector of the tumor microenvironment known as 
the onco-regenerative niche (ORN). We propose that tumor-derived Apo-EVs are signifi-
cant vehicles of the ORN, functioning as critical intercellular communicators that activate 
oncogenic tissue repair and regeneration pathways. We highlight important outstanding 
questions and suggest that Apo-EVs may harbor novel therapeutic targets.
Keywords: extracellular vesicles, apoptosis, inflammation and cancer, tumor microenvironment, angiogenesis, 
tissue repair and regeneration, macrophage activation, tumor biology
iNtrODUctiON: APOPtOsis, AND tHe ONcO-reGeNerAtive 
NicHe (OrN)
In addition to its activities in developmental sculpting and adult tissue involution, apoptosis is 
renowned for its capacity to regulate tissue turnover and homeostasis in which, simplistically, the 
expansion of cell populations is balanced by regulated cell death (and vice versa). In cancer, this 
balance between cell gain and cell loss becomes dysregulated, resulting in accumulation of tumor 
cells and net growth of neoplastic tissues (Figure 1). By effecting controlled cell deletion, apoptosis 
imposes a brake on oncogenesis, a logical concept that has long been proven and is widely accepted. 
Indeed, inhibition of the tumor suppressor function of apoptosis led to the categorization of a new 
class of oncogenes—BCL2 being the prototypic member—that could promote cell survival through 
suppression of apoptosis and thereby impose an oncogenic imbalance on the cell birth/cell death 
equation (1). Furthermore, the apoptosis effector protease, caspase-8, is mutated in multiple cancer 
types and the survival pathway PI3K/Akt/mTOR is dysregulated frequently in tumors (2). By contrast, 
FiGUre 1 | Left: oncogenic extracellular vesicle (EV) networks in the onco-regenerative niche (ORN). Schematic representation of the ORN illustrating the potential 
roles of Apo-EVs from dying tumor cells (Apo) in providing oncogenic signals to neighboring cells in the niche, exemplified by macrophages (M), viable tumor cells 
(Tu), and endothelial cells (E). We propose that Apo-EVs target such cells and modulate cellular functions, including macrophage polarization toward a reparative 
phenotype (M2-like activation state), promotion of tumor cell survival and proliferation, and angiogenesis. EVs from viable cells (Via-EVs) of tumor and stromal cell 
origin also seem likely to participate in these processes. Right: mechanisms of cell targeting and modulation by (Apo)-EVs. Examples of possible modes of 
interaction of Apo-EVs with target cells that may lead to modulation of cellular functions with or without transfer of intact EV cargoes (biologically active cargoes 
represented by small red circles). 1. Membrane fusion (receptor-dependent or -independent) permits transfer of EV cargoes to cytosolic locations. 2. Docking of  
EVs through receptor–ligand interaction may activate intracellular signaling pathways in the absence of cargo transfer. Ligands such as phosphatidylserine (PtdSer) 
(green) exposed at EV surfaces may interact directly or indirectly with target cell receptors (examples in the case of PtdSer including BAI1, TIM-4, Stabilin 2, Axl, Mer, 
as well as integrins αvβ3 and αvβ5). 3. Endocytic pathways (including phagocytosis) resulting in lysosomal degradation of cargoes are also likely to modulate cellular 
functions such as through metabolite supply and via receptor ligation. 4. Putative endocytic uptake of EVs without lysosomal degradation. We propose that Apo-EV 
cargoes are transferred intact to multiple intracellular compartments via this type of pathway.
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pro-apoptotic regulators such as p53 and BIM (3) among others 
have firmly established tumor-suppressive roles for apoptosis. 
For these and other reasons, the capacity to evade apoptosis has 
become a well-accepted hallmark of cancer (4).
However, set opposite its tumor suppressor functions, the apop-
tosis machinery can endow dying cells with the ability to stimulate 
proliferation of neighboring cells, either as part of developmental 
programmes or in tissue repair and regeneration in adult tissues 
(5–9). High levels of apoptosis are commonly associated with 
poor prognosis in multiple cancer types (10–17) and expression 
of pro-apoptotic effector molecules such as active Caspase-3 and 
Bax can correlate with aggressive disease (18, 19). Furthermore, 
low-level activation of the apoptosis programme can promote 
genomic instability and oncogenic transformation (20).
Emerging evidence suggests strongly that both constitutive 
and therapy-induced apoptosis can engender pro-oncogenic 
responses that enhance tumor growth and cause post-therapeutic 
relapse (21–24). In this scenario, tumor-cell apoptosis itself 
promotes imbalance in the cell birth/cell death equation that 
ultimately favors net tumor growth. Such regenerative effects 
of apoptosis in the context of the tumor microenvironment 
led one of us to propose recently the concept of the ORN: a 
tumor-promoting network of tumor cells, stromal cells, and 
immune cells which, together with associated extracellular com-
ponents, including EVs, soluble factors and matrix molecules, 
is orchestrated by tumor-cell apoptosis (Figure 1) (25, 26). We 
speculate that pervasive apoptotic tumor cell-derived signals 
in the ORN provide important pathways for tumor growth, 
metastasis and to post-therapeutic relapse. Here, we consider the 
potential roles of apoptotic tumor cell-derived EVs in providing 
such signals.
APO-evs AND APOPtOtic BODies
It is becoming increasingly clear that EVs are important intercel-
lular communication vehicles in the tumor microenvironment, 
shuttling an array of biologically active molecules reciprocally 
between tumor and non-tumor cells, modulating the develop-
ment of primary tumors and metastases. We propose that 
Apo-EVs—as well as EVs generated in viable cells responding 
to their apoptotic neighbors—are important elements of the 
ORN (Figure 1). EV production is a well-established hallmark 
of apoptosis, as is surface blebbing (zeiosis) of the plasma 
membrane in cells responding to apoptosis stimuli. Blebs may be 
important precursors to Apo-EVs, but it remains unclear to what 
extent the process of surface blebbing is related mechanistically 
to the production of Apo-EVs. Here, we use the term “Apo-EV” 
to encompass all classes of subcellular vesicles produced as a 
consequence of apoptosis. These include small (~50–1,000 nm) 
as well as larger vesicles (1 to several microns in diameter), often 
FiGUre 2 | Considerations of vesicular cargoes in relation to extracellular vesicle (EV) sizes. Schematic representations of Apo-EVs of ~500 nm (left) and 50 nm 
(right) are shown with delimiting lipid bilayer (green), a small mitochondrion (brown), ribosomes (gray), and examples of surface proteins all drawn approximately to 
scale. Note the significant potential impact of surface molecule size on total vesicle size in the case of small vesicles displaying relatively large surface molecules 
[measurement and representation of cell surface proteins adapted from Ref. (29)].
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referred to as “apoptotic bodies,” which harbor caspase-modified 
autoantigens, nuclear remnants containing condensed chro-
matin, and well-defined organelles, such as mitochondria and 
endoplasmic reticulum. Among the smaller vesicles are likely to 
be exosomes of endosomal pathway origin and budding plasma 
membrane EVs also known as microvesicles or ectosomes (27). 
As with all EVs, the size of Apo-EVs matters—not only in relation 
to what molecular and organelle cargoes can be carried but also 
with respect to the specific contribution of molecular cargoes, 
such as cell surface proteins, to overall EV size (Figure 2). While 
Apo-EVs are undoubtedly heterogeneous both in size and content 
(28), the underlying causes of this heterogeneity remain obscure.
APO-ev PrODUctiON MecHANisMs
During apoptosis, caspase-dependent cleavage, and activation 
of Rho-activated kinase, ROCK I alters actomyosin contractility, 
resulting in membrane blebbing (30). Blebbing occurs inde-
pendently of altered K+ and Cl− channel activity that results in 
increased K+ permeability and the reduction of cell volume that 
accompanies apoptosis. Instead, bleb formation occurs as a con-
sequence of detachment of the plasma membrane from the actin 
cortex and increased hydrostatic pressure generated by the acto-
myosin system (31). As a consequence, there is rapid local influx 
of cytosolic material and “ballooning” of the membrane, resulting 
in bleb enlargement. Although cytoskeletal proteins are lacking in 
newly formed blebs, as blebbing progresses, there is reassembly of 
the cortical cytoskeleton underneath the membrane. Treatment 
of cells with the ROCK inhibitor Y-27632 reduces both the forma-
tion of apoptotic bodies and the capacity for apoptotic-cell clear-
ance (32). Formation of small Apo-EVs may also be regulated 
through similar ROCK-dependent mechanisms (33), as are EVs 
generated by a variety of tumor cell types (34).
It has been widely assumed that the plasma membrane of 
apoptotic cells, apoptotic blebs, and Apo-EVs are molecularly 
homogeneous, displaying broadly similar changes, such as phos-
phatidylserine (PtdSer) exposure. However, there is evidence that 
apoptotic bodies exhibit loss of membrane integrity that allows 
limited molecular exchange (35), which may allow selective 
release of molecules that are able to modulate innate inflamma-
tory mechanisms. Protein release from apoptotic bodies, particu-
larly of nucleosomal histones, was reduced following inhibition 
of activity of either ROCK or myosin ATPase (35). Loss of mem-
brane permeability may be phased as apoptosis progresses, prior 
to the catastrophic loss of membrane integrity during secondary 
necrosis. Formation of Apo-EVs and gradual loss of membrane 
permeability could represent a mechanism to provide transient 
protection of proteins from local proteolytic degradation and/or 
clearance, potentially allowing signals relating to cellular demise 
to be disseminated distally, for example to other parts of the 
tumor microenvironment and to metastatic sites.
Studies of the recognition and phagocytosis of apoptotic 
cells have revealed potentially contrasting roles for membrane 
blebbing and the formation of apoptotic bodies. Formation of 
apoptotic blebs may promote phagocytosis of apoptotic cells. 
Compromised apoptotic cell uptake following inhibition of bleb-
bing (36) could be partially reversed by addition of the PtdSer 
opsonin, MFG-E8. Other phospholipid binding proteins such as 
C1q have been demonstrated to bind avidly to apoptotic blebs 
and C1q binds to neuronal blebs, acting to augment phagocytosis 
by microglia (37). ROCK-dependent high-density opsonization 
of apoptotic blebs could generate a topology that promotes 
phagocyte recognition, providing an explanation for why low-
level PtdSer exposure is not sufficient to signal phagocytosis of 
viable cells. Thus, membrane blebbing likely facilitates mainte-
nance of self-tolerance and suppression of antitumor immunity 
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through direct effects on apoptotic cell clearance. Other phe-
nomena related to vesiculation during apoptosis have also been 
noted recently. Following the description of apoptopodia—fine 
protuberances from apoptotic cells that appear to be involved 
in the release of larger varieties of Apo-EVs (>1 µm) (38)—EV 
production from certain apoptotic cell types has been observed 
to involve fragmentation of membrane protrusions resembling 
beads on a string (39). While the significance of these observa-
tions has not been fully elucidated, they provide clues as to the 
molecular events underlying the production of Apo-EVs and 
their cargo loading preferences. Intriguingly, Apo-EVs produced 
from beaded apoptopodia were found to be depleted of nuclear 
components including histones and nuclear DNA (39) that are 
well-known constituents of apoptotic bodies (40).
cArGOes AND FUNctiONAL Activities
While EVs ostensibly of non-apoptotic cell origins have been 
the subject of intense research in cancer biology in recent years, 
the biology of Apo-EVs remains less clear. Following on from 
seminal work showing that glioblastoma EVs carry RNA and 
protein cargoes having tumor growth-promoting properties and 
utility as diagnostic biomarkers (41), a wealth of evidence now 
implicates EVs in regulating tumor growth and metastatic spread 
through control of angiogenesis, drug resistance, and antitumor 
immunity. Furthermore, the roles of EVs in intercellular com-
munication in the tumor microenvironment are becoming better 
defined. Taking some recent examples, in murine melanoma, 
tumor cell-derived exosomes have been reported to promote 
the accumulation of pro-tumor macrophages via their ability to 
educate mesenchymal stromal cells which, like tumor-associated 
macrophages, are able to promote malignant disease via multiple 
modes, including growth factor production, suppression of 
antitumor immunity and angiogenesis (42). EVs from circulat-
ing tumor cells are also generated under conditions of shear flow. 
These EVs may play important roles in establishing the metastatic 
niche in the lung through interaction with the lung vasculature 
and rapidly accumulating myeloid cells (which phagocytose 
them) (43). It is noteworthy that EVs provide an intercellular 
signaling mechanism to transfer drug resistance to susceptible 
cells. For example, transfer of resistance to the multi-receptor 
tyrosine kinase inhibitor drug, Sunitinib can be achieved by a 
long, non-coding RNA (lncARSA) which acts by competing for 
binding to mir-34 and mir-449 to promote AXL and c-MET 
expression in renal cell carcinoma cells by carriage in exosomes 
and transfer to susceptible cells, thereby propagating resistance 
(44). Intriguingly, EVs isolated from cancer-associated fibroblasts 
are able to alter the metabolic profile of pancreatic tumor cells 
that interact with, and internalize them (45). Metabolic repro-
gramming by EVs involved inhibition of oxidative phospho-
rylation by mitochondria resulting in promotion of glycolysis 
and glutamine-dependent reductive carboxylation (46) in the 
recipient tumor cells. Furthermore, EVs were found to be capable 
of transferring multiple metabolic constituents including amino 
acids, lipids, citrate, and pyruvate among others, to tumor cells 
endowing them with the capacity to grow in nutrient-deficient 
media in vitro (45). These results strongly support the notion that 
EVs in the tumor microenvironment provide tumor cells with 
critical metabolic signals and constituents which permit growth 
of tumor clones under conditions of stress such as hypoxia and 
nutrient deprivation.
The extent to which Apo-EVs—including the larger variety, 
apoptotic bodies—can perform similarly diverse functions to 
their non-apoptotic counterparts awaits detailed clarification. 
However, several studies would tend to suggest that Apo-EVs 
represent far more than biological “waste disposal” units. We 
support the definition of Apo-EVs as those EVs, regardless of 
size or cargo, that are produced as a consequence of activation 
of the apoptosis effector machinery (such as executioner caspase 
activation) and that ultimately results in cell death. Thus, active 
Apo-EV production presages cell death and a major challenge 
for the allocation of functional properties to Apo-EVs specifically 
will be their discrimination from EVs produced by cells activated 
by other (for example, stress) pathways, including those en route 
to apoptosis. Like all EVs, Apo-EVs are overtly heterogeneous 
as illustrated by their size profile alone, which, ranges from 
around 30 nm to several microns (47, 48). To what extent size 
of Apo-EVs relates to functional properties is largely unknown, 
although small EVs (30–100  nm, which the authors termed 
“exosome-like”) produced by vascular endothelial cells down-
stream of caspase-3 activation were found to be distinct from 
their larger counterparts (microvesicles and apoptotic bodies) 
both in cargo composition and biological function (48). Vascular 
endothelial cell-derived apoptotic bodies carry histones and 
other nuclear proteins as well as abundant markers of organelles 
including mitochondria, endoplasmic reticulum, and ribosomes 
(48), confirming observations of apoptotic body cargoes in other 
systems. By contrast, the exosome-like EVs were found to be 
enriched in lysosomal, basement membrane and extracellular 
matrix proteins (48). Intriguingly, certain hallmark proteins of 
exosomes, including TSG101, CD9, and CD81, were missing 
from the exosome-like EVs whereas others, notably fibronectin, 
syntenin and translationally controlled tumor protein (TCTP) 
were present. Critically, exosome-like EVs were found to be 
immunogenic, in contrast to apoptotic bodies (48), confirming 
the presumption that the latter, as major remnants of apoptotic 
cells, are generally tolerogenic.
These recent studies extend earlier investigations demon-
strating the segregation of nuclear components into granular 
and vesicular structures and extrusion from the cell in EV-like 
structures and apoptotic bodies (49–54). Strikingly, DNA and 
RNA from apoptotic cells have been described as segregating 
into non-overlapping vesicular entities, adding to the complexity 
of Apo-EV heterogeneity. It is well established that the blebs of 
apoptotic cell surfaces harbor antigens of common significance in 
autoimmune disease, including the ribonucleoproteins La and Ro 
and nucleosomal DNA (55). The immunogenicity of exosome-
like EVs from apoptotic endothelial cells adds a further dimen-
sion to this phenomenon. Thus, the C-terminal fragment (LG3) 
of the basement membrane component Perlecan carried by the 
exosome-like EVs is highly immunogenic and may be responsible 
for the production of autoantibodies that can severely compro-
mise successful renal transplantation (48). Substantial further 
investigations are warranted in order to clarify the differential 
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capacity of apoptotic cells and their derived vesicles to modulate 
tolerance and immunity.
Besides immuno-regulatory properties, Apo-EVs have addi-
tional functional attributes based, like other EV classes, on their 
ability to transfer bioactive molecules to “target” cells. For example, 
apoptotic bodies (1–4 µm) derived from mature endothelial cells 
have been shown to stimulate the proliferation and differentiation 
of circulating endothelial progenitor cells (56). Indeed, Apo-EVs 
of endothelial cell origin carry a variety of biologically active 
components in addition to the aforementioned immunogenic 
Perlecan LG3, including TCTP, which can inhibit apoptosis in 
vascular smooth muscle cells (57). Apo-EVs may also allow the 
transfer of intact organelles between cells. In this context, it is 
noteworthy that mitochondrial transfer via EVs may represent 
an important response to stressful conditions as exemplified by 
the transfer of intact mitochondria from astrocytes to neurons in 
order to provide survival signals during the ischemic conditions 
of stroke (58). One of the most intriguing cargoes of Apo-EVs is 
genomic DNA since it has been shown that apoptotic bodies are 
able to mediate the horizontal transfer of DNA between somatic 
cells. While the details of the modes of transfer and fundamental 
roles of Apo-EVs (versus the remnants of apoptotic cells) have 
not been studied, DNA from apoptotic cells can undoubtedly be 
transferred to neighboring cells including tumor cells, endothe-
lial cells, fibroblasts, and macrophages leading to apoptotic 
cell-derived gene expression in the recipient cells. In normal 
physiology, cells are protected by a DNA damage response requir-
ing DNAse II, Chk2, and p53/p21, and deficiency in p53 and p21 
can ultimately render murine embryonic fibroblasts oncogenic 
following transfer of DNA from apoptotic cells harboring c-myc 
or H-Ras oncogenes in combination with a drug resistance gene 
(59–61). These results have significant implications not only for 
genomic stability and heterogeneity of tumor cells but also for the 
acquisition of aberrant DNA by non-tumor cell components of 
the ORN, notably endothelial cells, macrophages and fibroblasts, 
all of which have known capacity to engulf apoptotic cells and 
bodies. Such genetic changes in the ORN could provide impor-
tant pro-oncogenic signals even if the resultant “exogenous” gene 
expression is transient.
cONcLUsiON AND FUtUre 
PersPectives
While it is clear that the breakdown of apoptotic cells into mem-
brane-bounded fragments of broad size ranges varies between 
different cell types, the full extent of the functional properties 
of Apo-EVs remains unknown. It has been reported that forma-
tion of “bite-sized” apoptotic bodies can aid in the phagocytic 
clearance of dying cells (36). This may be important for the 
apoptotic-cell clearance processes of so-called non-professional 
(i.e., non-macrophage) phagocytes. However, macrophages and 
other phagocytes have overt capacity to engulf whole apoptotic 
cells rapidly (62). We propose that the most important func-
tion of Apo-EVs in the context of cancer is the propagation of 
intercellular signals of fundamental importance to the ORN. 
Understanding their modes of interaction with recipient cells, 
their mechanisms of internalization and intracellular process-
ing will be crucial to understanding fully the physiological and 
pathological attributes of Apo-EVs. To date, virtually nothing 
is known of these processes, although it may be expected that 
some clearance/engulfment mechanisms of apoptotic cells and 
Apo-EVs will prove to share molecular components (Figure 1). 
It is noteworthy in this context that PtdSer exposed on EVs is 
involved in their uptake by target cells expressing PtdSer recep-
tors such as TIM-4, known for phagocytosis of apoptotic cells 
(63). A critical question is whether endocytosed or phagocytosed 
Apo-EV cargo is necessarily degraded by lysosomes, as is gener-
ally assumed. Thus, the targeting mechanisms of Apo-EVs along 
with the destinies of their cargoes require detailed clarification.
Pro-inflammatory extracellular vesicles (EVs) are produced 
by macrophages responding to ATP via P2X7 receptors. It has 
been reported recently that this results in NLPR3 inflamma-
some activation in human macrophages, which consequently 
undergo vesicle-mediated unconventional secretion of IL-1β 
(64). Conversely, alveolar macrophage-derived EVs have been 
shown to suppress airway inflammation (65). Thus, the vesicular 
inter communication that results from tissue damage is likely 
to involve a varied mix of vesicle populations, including pro- 
and anti-inflammatory, derived not only from dying cells but 
also from their responsive neighbors or recruited phagocytes 
(Figure  1). Since the ORN represents a sector of the tumor 
microenvironment engaged in dysregulated, cell death-driven 
tissue repair and regeneration, it seems likely that the intercellular 
communications so achieved by EVs of the ORN will prove to 
overlap with those in healing or chronic wounds. Future work 
aimed at identifying the underlying mechanisms may yield novel 
molecular targets for both cancer and wound treatments.
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